Zobrazeno 1 - 10
of 11
pro vyhledávání: '"Colin M. Hayes"'
Autor:
John M. Maris, Jo Lynne Rokita, Laura Scolaro, Colin M. Hayes, Komal S. Rathi, Alvin Farrel, Grace E. Coggins
Figure S5 shows the confirmation of differential gene expression between RNA seq samples.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::124664b1e08a8185e67cf472a06c29a3
https://doi.org/10.1158/0008-5472.22422431.v1
https://doi.org/10.1158/0008-5472.22422431.v1
Autor:
John M. Maris, Jo Lynne Rokita, Laura Scolaro, Colin M. Hayes, Komal S. Rathi, Alvin Farrel, Grace E. Coggins
Figure S6 shows a motif analysis indicating TEAD1-4 consensus sites present at the MYCN gene locus.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::08b0b01c558a4158db11e48c54583c44
https://doi.org/10.1158/0008-5472.22422428.v1
https://doi.org/10.1158/0008-5472.22422428.v1
Autor:
John M. Maris, Jo Lynne Rokita, Laura Scolaro, Colin M. Hayes, Komal S. Rathi, Alvin Farrel, Grace E. Coggins
Relapsed neuroblastomas are enriched with activating mutations of the RAS–MAPK signaling pathway. The MEK1/2 inhibitor trametinib delays tumor growth but does not sustain regression in neuroblastoma preclinical models. Recent studies have implicate
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7ab51a3f2c94f7ae7c340d290ebf0faa
https://doi.org/10.1158/0008-5472.c.6511223.v1
https://doi.org/10.1158/0008-5472.c.6511223.v1
Autor:
John M. Maris, Jo Lynne Rokita, Laura Scolaro, Colin M. Hayes, Komal S. Rathi, Alvin Farrel, Grace E. Coggins
Table S1 includes MYCN amplification and chromosome 11q status across a panel of 16 neuroblastoma cell lines. Table S2-4 include differentially-expressed genes identified in each of the three differential expression analyses. Table S5 includes unique
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2e4312d248a9a197bbe42a3d91c36147
https://doi.org/10.1158/0008-5472.22422452.v1
https://doi.org/10.1158/0008-5472.22422452.v1
Autor:
John M. Maris, Jo Lynne Rokita, Laura Scolaro, Colin M. Hayes, Komal S. Rathi, Alvin Farrel, Grace E. Coggins
Figure S2 shows Sanger sequencing of NLF YAP1 knockout isogenic lines used to confirm mutational status.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2a70d9c4fcc726690ebc59568a11fd82
https://doi.org/10.1158/0008-5472.22422443
https://doi.org/10.1158/0008-5472.22422443
Autor:
John M. Maris, Jo Lynne Rokita, Laura Scolaro, Colin M. Hayes, Komal S. Rathi, Alvin Farrel, Grace E. Coggins
This file includes figure legends corresponding to Supplementary Figures S1-6.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::18efd922ceccdbda80b59279f0102976
https://doi.org/10.1158/0008-5472.22422449
https://doi.org/10.1158/0008-5472.22422449
Autor:
John M. Maris, Jo Lynne Rokita, Laura Scolaro, Colin M. Hayes, Komal S. Rathi, Alvin Farrel, Grace E. Coggins
Figure S3 shows that growth rates of NLF YAP1-null clones are slower than NLF sgCon.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bb51c6b2dfcd0dd3b7b48958344ae271
https://doi.org/10.1158/0008-5472.22422440.v1
https://doi.org/10.1158/0008-5472.22422440.v1
Autor:
John M. Maris, Jo Lynne Rokita, Laura Scolaro, Colin M. Hayes, Komal S. Rathi, Alvin Farrel, Grace E. Coggins
Figure S1A shows the two CRISPR gRNA targets. Figure S1B-E shows YAP1 knockout pools in neuroblastoma cell lines are sensitized to trametinib.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3ea5382cc81b103d803c266477de9a41
https://doi.org/10.1158/0008-5472.22422446.v1
https://doi.org/10.1158/0008-5472.22422446.v1
Autor:
Jo Lynne Rokita, Laura Scolaro, John M. Maris, Colin M. Hayes, Grace E. Coggins, Komal S. Rathi, Alvin Farrel
Publikováno v:
Cancer Res
Relapsed neuroblastomas are enriched with activating mutations of the RAS–MAPK signaling pathway. The MEK1/2 inhibitor trametinib delays tumor growth but does not sustain regression in neuroblastoma preclinical models. Recent studies have implicate
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e4da5d3987847aa574db4d1ea688d143
https://doi.org/10.1158/0008-5472.can-19-1415
https://doi.org/10.1158/0008-5472.can-19-1415
Autor:
Grace E. Coggins, Alvin Farrel, Komal S. Rathi, Leonard Post, John M. Maris, Colin M. Hayes, Tracy Tang
Publikováno v:
Cancer Research. 79:2886-2886
Background: Relapsed NBs harbor an enrichment in mutations activating RAS-MAPK signaling pathway. The MEK1/2 inhibitor trametinib has shown tumor growth delay but not regressions in NB preclinical models. Recent studies have implicated the Hippo path
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4464e1b19c1355a9ebb03c00e4d88faa
https://doi.org/10.1158/1538-7445.am2019-2886
https://doi.org/10.1158/1538-7445.am2019-2886